Among the millions who have turned to GLP-1 medications like Ozempic as a cornerstone of modern diabetes care, roughly one in ten carry a quiet genetic difference that renders these drugs less effective — not through any failure of the medicine itself, but through a deeper biological resistance written into their DNA. Researchers at Stanford Medicine have traced this resistance to variants in genes governing a hormone-activating enzyme called PAM, offering the first molecular explanation for why some patients plateau where others thrive. The discovery opens a door toward precision medicine in
Rádio Pampa
· Jun 08, 2026
· health
· 3 min read
High
Sourcing: Verified
Genetic variants explain why Ozempic fails for 10% of patients
◉
Health & Medicine
2746 related articles
Ozempic and GLP-1 drugs: how the weight-loss revolution works and what…
O GLOBO · 99% match
Anvisa aprova remdesivir contra covid-19 e registra vacina de Oxford
Jornal de Brasília · 90% match
Brazil Gets New Blood Test for Early Alzheimer's Detection
Olhar Digital · 90% match
Brazil's obesity guidelines shift focus from weight loss to disease ma…
Correio Braziliense · 90% match
Eli Lilly's retatrutida shows 28% weight loss in trials, rivaling bari…
Poder360 · 90% match
Related Coverage
G1 · Aug 20
Pai agradece médicos após morte de gêmeas unidas pela cabeça: 'mais vitórias que derrotas'
Pai das gêmeas unidas pela cabeça que morreram em cirurgia de separação agradece empenho de mais de 50 profissionais do …
Folha de S.Paulo · Aug 20 Selton Mello se emociona ao receber Kikito de Cristal em GramadoSelton Mello recebeu o Kikito de Cristal no Festival de Gramado e se emocionou ao lembrar que era a primeira vez receben…
G1 · Aug 20 CEMEI Amiguinhos da Vila inaugura prédio moderno com capacidade para 320 alunosInaugurado novo prédio do CEMEI Amiguinhos da Vila em Montes Claros, com capacidade para 320 alunos, oito salas de aula,…
Folha de S.Paulo · Aug 20 Hepatites D e E circulam no Brasil e preocupam especialistasRevisão de 200 estudos com dados de 14,5 milhões de pessoas revela que hepatites D e E circulam no Brasil com prevalênci…
Bias & Framing
No detailed analysis data available for this lens. Try re-running lenses from the admin panel.
Geopolitical Impact
🌎
Stanford research identifies genetic variants in 10% of people causing GLP-1 resistance, with limited geopolitical implications but potential for precision medicine disparities between nations.
Escalation Risk
low
Confidence
MED
United States
European Union
Brazil
Global pharmaceutical markets
Advances in precision medicine genetics strengthen U.S. biotech leadership and Stanford's research influence. Unequal access to genetic testing and personalized treatments could widen healthcare disparities between developed and developing nations, affecting pharmaceutical market dynamics and healthcare policy globally.
Similar to the Human Genome Project era (2000s), where genetic discoveries concentrated research power in wealthy nations, potentially creating healthcare inequities between countries with advanced genomic infrastructure and those without.
Economic Lens
📈
Stanford researchers identify genetic variants in 10% of people causing GLP-1 resistance, explaining poor Ozempic efficacy in some diabetes patients and enabling precision medicine approaches.
Market Signal
mixed
Confidence
HIGH
Pharmaceutical/Biotechnology
Healthcare/Medical Services
Diagnostic Testing
Health Insurance
Patients with GLP-1 resistance variants may benefit from earlier identification enabling alternative treatments, reducing ineffective medication use and healthcare costs. However, genetic testing costs may increase upfront expenses for some consumers.
Potential regulatory push for genetic screening before GLP-1 prescription; insurance coverage decisions for pharmacogenomic testing; FDA guidance on precision medicine approaches for diabetes treatment; healthcare systems may adopt genetic profiling protocols.